Medivation under pressure over Dimebon; CEO contests market skepticism on promise to move directly into Phase III (Financial Times)
This article is provided to FT.com readers by Pharmawire a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market.

Neupro(R) Filed With The FDA For The Treatment Of Advanced-Stage Parkinson's Disease (Medical News Today)
UCB announced that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as adjunctive therapy with levodopa in adult patients with advanced-stage Parkinson's disease has been accepted for filing by the U.S. Food and Drug Administration (FDA). [click link for full article]